Overactive bladder: the importance of tailoring treatment to the individual patient
- PMID: 21847345
- PMCID: PMC3155853
- DOI: 10.2147/JMDH.S21401
Overactive bladder: the importance of tailoring treatment to the individual patient
Abstract
Introduction: Overactive bladder (OAB) is a prevalent and persistent condition that is often under-diagnosed and under-treated, and which frequently requires tailored treatment for successful management.
Methods: This consensus opinion-based review summarizes the discussions of a group of experts in the field of OAB that were assembled to evaluate the importance of correct diagnosis and appropriate pharmacotherapy in patients with OAB.
Results: A thorough diagnostic process is crucial for allowing exclusion of underlying medical issues and differentiation from genitourinary conditions other than OAB. In addition, selecting the most appropriate pharmacotherapy needs to be carefully considered in the context of each patient with OAB. In general, patients with OAB tend to be older with various comorbidities and often receiving multiple concomitant medications. Treatment decisions should take into consideration the differing potential for antimuscarinic medications to alter cognitive and cardiovascular functions, both of which may be compromised in this patient population.
Conclusion: Tailoring treatment to individual patients by comprehensive patient assessment may lead to more effective management of patients with OAB, especially those receiving polypharmacy for comorbidities.
Keywords: antimuscarinics; cardiovascular; cognitive function; diagnosis; overactive bladder.
Figures


Similar articles
-
Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder.BJU Int. 2010 Jul;106(2):268-74. doi: 10.1111/j.1464-410X.2009.09073.x. Epub 2009 Nov 17. BJU Int. 2010. PMID: 19922546
-
Overactive bladder in the elderly: a guide to pharmacological management.Drugs Aging. 2005;22(12):1013-28. doi: 10.2165/00002512-200522120-00003. Drugs Aging. 2005. PMID: 16363885 Review.
-
Evaluating Outcomes in Patients with Overactive Bladder within an Integrated Healthcare Delivery System Using a Treatment Patterns Analyzer.Am Health Drug Benefits. 2016 Sep;9(6):343-353. Am Health Drug Benefits. 2016. PMID: 27924187 Free PMC article.
-
Treatments for overactive bladder: focus on pharmacotherapy.J Obstet Gynaecol Can. 2012 Nov;34(11):1092-1101. doi: 10.1016/S1701-2163(16)35440-8. J Obstet Gynaecol Can. 2012. PMID: 23231848
-
Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment.Eur Urol. 2019 Dec;76(6):767-779. doi: 10.1016/j.eururo.2019.07.010. Epub 2019 Aug 13. Eur Urol. 2019. PMID: 31416636 Review.
Cited by
-
The prevalence of detrusor overactivity amongst patients with symptoms of overactive bladder: a retrospective cohort study.Int Urogynecol J. 2012 Nov;23(11):1577-80. doi: 10.1007/s00192-012-1781-4. Epub 2012 Apr 25. Int Urogynecol J. 2012. PMID: 22531957
-
A patient-reported, non-interventional, cross-sectional discrete choice experiment to determine treatment attribute preferences in treatment-naïve overactive bladder patients in the US.Patient Prefer Adherence. 2018 Oct 12;12:2139-2152. doi: 10.2147/PPA.S178668. eCollection 2018. Patient Prefer Adherence. 2018. PMID: 30349208 Free PMC article.
-
The Problem of Polypharmacy in Female Patients with Overactive Bladders - Cross-Sectional Study in a Specialist Outpatient Department.Geburtshilfe Frauenheilkd. 2016 Dec;76(12):1318-1324. doi: 10.1055/s-0042-114221. Geburtshilfe Frauenheilkd. 2016. PMID: 28042169 Free PMC article.
-
Rationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effects.Korean J Urol. 2013 Dec;54(12):806-15. doi: 10.4111/kju.2013.54.12.806. Epub 2013 Dec 10. Korean J Urol. 2013. PMID: 24363860 Free PMC article. Review.
References
-
- Haylen BT, De Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4–20. - PubMed
-
- Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–1314. - PubMed
-
- Garnett S, Swithinbank L, Ellis-Jones J, et al. The long-term natural history of overactive bladder symptoms due to idiopathic detrusor overactivity in women. BJU Int. 2009;104(7):948–953. - PubMed
-
- Malmsten UG, Molander U, Peeker R, Irwin DE, Milsom I. Urinary incontinence, overactive bladder, and other lower urinary tract symptoms: a longitudinal population-based survey in men aged 45–103 years. Eur Urol. 2010;58(1):149–156. - PubMed
-
- Abrams P, Wein A. The overactive bladder: a widespread but treatable condition. Stockholm: Erik Sparre Medical AB; 1998.
LinkOut - more resources
Full Text Sources